Currently, although HCC surveillance using ultrasound and serum AFP, imaging‐based diagnosis (CT, MRI), and the new therapeutic methods such as local ablation and transarterial chemoembolization have been shown to be beneficial in increasing survival time, recent data show that the sensitivity of HCC surveillance is still low (about 60%) and that some HCC patients had impaired liver function contradictory to undergoing TACE.11 Here, AFP is linked to hepatocellular carcinoma.